Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep1025 | Hot topics (including COVID-19) | ECE2020

Medications used by individuals with fibrodysplasia ossificans progressiva (FOP): Data from a global natural history study

C. Hsiao Edward , Al Mukaddam Mona , Baujat Geneviève , De Cunto Carmen , Keen Richard , J Pignolo Robert , Harnett Kathleen , Marino Rose , Kaplan Frederick S

Background: FOP is an ultra-rare genetic disorder characterised by episodic progressive heterotopic ossification (HO) and flare-ups, causing cumulative disability and early death. FOP is diagnosed and managed by multiple specialists, including endocrinologists. There are no established disease-modifying therapies to prevent HO in FOP. Treatment guidelines for symptomatic relief of FOP have recently been published by the International Clinical Council on FOP (ICC).1<...

ea0070aep1019 | Hot topics (including COVID-19) | ECE2020

A global natural history study of Fibrodysplasia Ossificans Progressiva (FOP): 12-month outcomes

Mukaddam Mona Al , Pignolo Robert J. , Baujat Geneviève , Brown Matthew A , De Cunto Carmen , Di Rocco Maja , Hsiao Edward C. , Keen Richard , Le Quan Sang Kim-Hanh , Strahs Andrew , Marino Rose , Kaplan Frederick S

Background: FOP is an ultra-rare, severely disabling genetic disorder characterised by cumulative heterotopic ossification (HO), often preceded by episodic flare-ups, leading to physical disability and early death. Initial misdiagnosis can occur in ~90% of individuals leading to unnecessary, often harmful interventions. FOP is diagnosed and managed by multiple specialists, including endocrinologists.Objective: A prospective, 36-month, global natural...

ea0056gp175 | Parathyroid | ECE2018

Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement

Mantovani Giovanna , Lecumberri Beatriz , Bastepe Murat , Monk David , de Sanctis Luisa , Thiele Susanne , Usardi Alessia , Ahmed Faisal , Bufo Roberto , Choplin Timothee , DeFilippo Gianpaolo , Devernois Guillemette , Eggermann Thomas , Elli Francesca , Freson Kathleen , Ramirez Aurora Garcia , Germain-Lee Emily , Groussin Lionel , Hamdy Neveen , Hanna Patrick , Hiort Olaf , Juppner Harald , Kamenicky Peter , Knight Nina , Kottler Marie-Laure , Le Norcy Elvire , Levine Michael A , Makitie Outi , Martin Regina , Martos-Moreno Gabriel Angel , Minagawa Masanori , Murray Philip , Pereda Arrate , Pignolo Robert , Rejnmark Lars , Rodado Rebecca , Rothenbuhler Anya , Saraff Vrinda , Shoemaker Ashley , Shore Eileen M , Silve Caroline , Turan Serap , Woods Philip , Zillikens M Carola , de Nanclares Guiomar Perez , Linglart Agnes

Pseudohypoparathyroidism (PHP) and related disorders lead to a wide spectrum of abnormal physical characteristics, neurocognitive and endocrine abnormalities that share a common PTH/PTHrP signaling pathway. The clinical and molecular overlap of PHP and related disorders lead to difficulties in clinical and molecular diagnosis which prompt to the possibility of incorrect management of these patients. PHP (including all subtypes), pseudoPHP, acrodysostosis and progressive osseou...